We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agenus (AGEN) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Agenus (AGEN - Free Report) closed the most recent trading day at $2.31, moving -1.28% from the previous trading session. This change lagged the S&P 500's 0.69% gain on the day. Meanwhile, the Dow gained 0.64%, and the Nasdaq, a tech-heavy index, lost 0.2%.
Heading into today, shares of the biotechnology company had lost 16.13% over the past month, lagging the Medical sector's loss of 5.7% and the S&P 500's loss of 9.94% in that time.
Wall Street will be looking for positivity from Agenus as it approaches its next earnings report date. In that report, analysts expect Agenus to post earnings of -$0.18 per share. This would mark a year-over-year decline of 126.09%. Meanwhile, our latest consensus estimate is calling for revenue of $19.86 million, down 92.15% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.70 per share and revenue of $82.14 million, which would represent changes of -536.36% and -72.22%, respectively, from the prior year.
Any recent changes to analyst estimates for Agenus should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Agenus is holding a Zacks Rank of #1 (Strong Buy) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 78, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Agenus (AGEN) Stock Sinks As Market Gains: What You Should Know
Agenus (AGEN - Free Report) closed the most recent trading day at $2.31, moving -1.28% from the previous trading session. This change lagged the S&P 500's 0.69% gain on the day. Meanwhile, the Dow gained 0.64%, and the Nasdaq, a tech-heavy index, lost 0.2%.
Heading into today, shares of the biotechnology company had lost 16.13% over the past month, lagging the Medical sector's loss of 5.7% and the S&P 500's loss of 9.94% in that time.
Wall Street will be looking for positivity from Agenus as it approaches its next earnings report date. In that report, analysts expect Agenus to post earnings of -$0.18 per share. This would mark a year-over-year decline of 126.09%. Meanwhile, our latest consensus estimate is calling for revenue of $19.86 million, down 92.15% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.70 per share and revenue of $82.14 million, which would represent changes of -536.36% and -72.22%, respectively, from the prior year.
Any recent changes to analyst estimates for Agenus should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Agenus is holding a Zacks Rank of #1 (Strong Buy) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 78, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.